Japan’s cannabinoid scene moves faster than you can say “CBD latte.” One month, a new acronym is everywhere; the next, it has vanished from shop menus, group chats, and the collective memory of anyone who does not enjoy regulatory paperwork.
This guide tracks cannabinoids and altnoids available in Japan, including familiar names such as CBD and CBG alongside newer compounds and proprietary blends. It is designed as a living field guide: a way to decode the labels, understand how products are commonly marketed, and spot which names belong in the “historical context” drawer.
A quick vocabulary check before we begin: cannabinoids are the broad umbrella, including CBD, CBG, THC, and many others. Altnoids is informal shorthand for newer or alternative cannabinoid products, often made by chemically converting hemp-derived starting materials. Not every cannabinoid is an altnoid, and not every altnoid is the same kind of thing.
👉 Below you’ll find a set of charts showing current altnoids available in Japan. Just keep in mind that the rules can change at any time. Explore with curiosity but proceed with caution. And if there’s something I’m missing, please let me know: maryjaneinjapan@gmail.com
⚠️ Important: This page is for general information, not legal or medical advice. Japan’s rules can change quickly. Product availability, formulations, and compliance can also change faster than I can update.
Regulatory update: CBN became a designated drug in Japan on June 1, 2026. It is included below for historical context only, not as a currently available consumer option.
How to Read This Guide
Each entry explains what the ingredient is generally described as, where it comes from, and how brands or users commonly talk about its effects. Those effect descriptions are not guarantees. Dose, formula, terpenes, tolerance, setting, food, mood, hormones, health, and whether Mercury is in retrograde can all change the experience.
For the bigger picture—including the difference between natural, semi-synthetic, and fully synthetic cannabinoids—read: What Are Altnoids?
Non-Intoxicating or Mildly Felt Cannabinoids
These cannabinoids are generally discussed as non-intoxicating, lighter, or more wellness-oriented than stronger-effect altnoids. That does not mean every product will feel identical, especially when brands start mixing several ingredients together.
CBD (Cannabidiol)
Status: Current market listing
What it is: A major naturally occurring cannabinoid found in hemp.
Origin: Hemp-derived.
Commonly marketed for: Everyday calm, wellness routines, and non-intoxicating products.
What to know: CBD is the familiar starting point for much of Japan’s cannabinoid market. It is generally not intoxicating in the way THC is, but quality and documentation can vary wildly from product to product.
Japan note: In order for CBD to be legal in Japan, it must be made with very specific parts of the plant and contain near non-detectable levels of THC. That means don’t bring any from abroad and only get CBD in Japan from reputable companies who adhere to all regulations in Japan. Look for current THC-compliance testing and clear product information, especially with vapes, oils, and imported products.
CBG (Cannabigerol)
Status: Current market listing
What it is: A naturally occurring cannabinoid often called the “mother cannabinoid,” because it is a precursor in the plant’s cannabinoid pathway.
Origin: Hemp-derived.
Commonly marketed for: Clear, daytime-friendly, focused-calm vibes.
What to know: CBG is often blended with CBD rather than sold on its own. It is commonly positioned as a lighter, more alert counterpart to CBD—although the whole formula matters more than the name.
CBN (Cannabinol)*
Status: *Historical context — regulated (illegal for possession and use) in Japan from June 1, 2026
What it is: A cannabinoid associated with the breakdown or oxidation of THC.
Origin: Naturally occurring in cannabis, often discussed in relation to aged THC.
Previously marketed for: Nighttime relaxation, sleep-oriented blends, and a heavier wind-down feel.
What to know: CBN was a major name in Japan’s cannabinoid market until its designation in 2026. It remains here because readers will still encounter it in older reviews, product pages, and screenshots from the Before Times.
Japan note: Do not treat older CBN listings as current consumer options. It is not legal to possess or use CBN in Japan without a medical certificate that requires a very specific process to obtain.
Read More: How to Get a Medical Certificate for CBN in Japan
CRD
Status: Current market listing
What it is: CRD is generally used to describe a stabilized cannabinoid distillate designed to resist (and help products resist) crystallization.
Origin: Blend distillate; formulas can include different cannabinoids depending on the supplier.
Commonly marketed for: A balanced cannabinoid experience shaped by the specific blend.
What to know: CRD is generally used to describe a stabilized cannabinoid distillate blend rather than one single cannabinoid. The exact ingredients and ratios can differ by product, so check the label or COA to see what is actually in that particular cart.
H4CBD (Hydrogenated Cannabidiol)
Status: Current market listing
What it is: A hydrogenated CBD-derived cannabinoid.
Origin: Commonly described as semi-synthetic, made from hemp-derived CBD.
Commonly marketed for: A fuller, more noticeable cannabinoid experience than standard CBD.
What to know: H4CBD is a hydrogenated CBD-derived cannabinoid. In Japan, it has appeared in products such as vapes and cannabinoid blends.
Mary Jane’s translation: CBD’s slightly more dressed-up cousin—not an automatic ticket to a THC-style high.
Read more: What is H4CBD?
Psychoactive or Stronger-Effect Altnoids
These are the ingredients and blends most often marketed as offering a more noticeable “high,” euphoric effect, or “THC-adjacent” experience. That does not mean every product is equally strong. It does mean the product page deserves more than a two-second glance.
CBX
Status: Current market listing / emerging ingredient
What it is: A newer converted cannabinoid material appearing in Japan as isolate and distillate. Sellers describe it as a C4-series material, made from hemp-derived cannabinoid starting materials through chemical conversion and purification.
Commonly marketed or reported as: Fast-onset, noticeable, clear and sativa-leaning, with a relatively quick, clean finish.
What to know: CBX is still very new, with limited public research and inconsistent disclosure of its exact composition. Do not assume every CBX-labelled product contains the same compounds or will feel the same.
Read more: What Is CBX?
THAH
Status: Current market listing
What it is: A newer cannabinoid ingredient that began appearing in Japan in 2026. It is unrelated to THA, despite the names being similar.
Origin: Reportedly a newer imported raw material or a blended raw material; nobody is saying for sure, and exact supplier details can vary by product.
Commonly marketed or reported as: Slow-building euphoric head effects, deep body relaxation, and couch-lock territory.
What to know: Brands have positioned THAH as a stronger option for experienced users, with effects that may build over 20–30 minutes.
Read more: What is THAH?
CPX and HHBD
Status: Current market listing
What it is: Newer CBD-derived cannabinoid ingredients often used in stronger-effect formulas.
Origin: Commonly described as lab-converted from hemp-derived starting materials; terminology can vary by seller.
Commonly marketed or reported as: Clearer, more daytime-friendly effects with a euphoric lift and a relaxed body feel.
What to know: CPX and HHBD are often presented as “functional” or “sativa-like” options, but the blend, percentage, and terpene profile can change the actual experience dramatically.
Read more: What is HHBD?
CRDP
Status: Current market listing
What it is: A psychoactive cannabinoid blend that became especially visible in Japan after first appearing in Thailand.
Origin: Developed in Thailand; commonly described as hemp-derived but chemically modified.
Commonly marketed or reported as: Uplifting, euphoric, moderate-to-strong effects, often with a heavier body component.
What to know: CRDP is frequently used in stronger vape formulas.
Read more: What is CRDP?
CRDB
Status: Current / market terminology varies
What it is: A CRD-style blend featuring four-carbon-chain compounds, developed as a clearer alternative to CRDP.
Origin: Lab-produced from hemp-derived cannabinoids; reportedly from the same manufacturer family as CRDP.
Commonly marketed or reported as: Fast onset, uplifting and focus-friendly at first, then a smoother hybrid-style calm.
What to know: It is a newer, supplier-led label, so check the exact product formula and COA rather than treating the name as a universal standard.
Read more: What is CRDB?
H4CBH
Status: Current market listing
What it is: A hydrogenated cannabinoid related to the HHC family, with its own modifications.
Origin: Lab-modified from hemp-derived starting materials.
Commonly marketed or reported as: Brighter, more social, head-forward, and one of the stronger altnoids on the market at the time of writing.
What to know: H4CBH has earned a reputation as one of the stronger-feeling newer ingredients in Japan. Experiences vary, and the percentage on a label is not the whole story.
Read more: What is H4CBH?
Previously Available and/or Now Regulated in Japan
These names are included because you may still see them in older reviews, archived product pages, or the occasional screenshot from someone’s 2024 group chat. They are not a current-use list.
CBN
Status: Designated drug in Japan from June 1, 2026
Previously marketed for: Nighttime relaxation and sleep-oriented blends
What changed: Japan’s Ministry of Health, Labour and Welfare added CBN to the designated-drug list, meaning ordinary manufacture, import, sale, possession, and use are prohibited.
HHC, HHCH, THCH and THCPO
Status: Previously sold, later regulated
What to know: These compounds are part of the earlier wave of high-effect cannabinoids that helped shape Japan’s current altnoid market. Their regulation is a reminder that “available now” is not the same thing as “available forever.”
THA
Status: No longer available following the June 2026 CBN-related regulatory change, based on product formulations/market withdrawal
What to know: THA was a blended raw material rather than one single cannabinoid, and it appeared in a number of products before the regulatory shift.
The Bottom Line
Japan’s altnoid market is fascinating, creative, occasionally bewildering, and never especially good at choosing names that are easy to pronounce after one coffee. Still, you do not need to memorize every acronym. You just need to know the broad difference between lighter cannabinoids and stronger-effect altnoids, read current product documentation, and check the date before assuming something is still part of the landscape.
If you have spotted a cannabinoid currently appearing in Japan that deserves a closer look, email me at maryjaneinjapan@gmail.com. I cannot promise I will add every mysterious letter-combo immediately, but I am always curious.
Last updated: July 3, 2026
Leave a Reply